Core Insights - The global market for GLP-1 drugs is rapidly expanding, with sales expected to exceed $50 billion in 2024, driven by the success of drugs like semaglutide, which generated $16.632 billion in sales in the first half of the year, surpassing competitors [1][10] - The Hong Kong market is witnessing significant interest in GLP-1 drug stocks, exemplified by the 270% surge in shares of Sinovant Biopharma during its IPO and a fourfold increase in shares of Pague Biopharma over three months, indicating strong investor enthusiasm for this sector [1][2] - Pague Biopharma is positioning itself as a challenger to established pharmaceutical giants like Novo Nordisk, with its core product PB-119 recently having its registration application accepted, and promising clinical data emerging for its other candidate PB-718 [1][5] Company Developments - Pague Biopharma has developed a proprietary platform (HECTOR®) for drug discovery, which includes a drug molecule design platform that enhances the stability and efficacy of compounds while reducing research costs [4] - The company is focusing on the development of PB-718, a dual receptor agonist targeting GLP-1 and GCGR, which shows potential for significant metabolic improvements and addresses the complex mechanisms of MASH, a previously challenging area for drug development [5][6] - Recent clinical trial results for PB-718 demonstrated a 57.14% reduction in liver fat content over 18 weeks, outperforming semaglutide's results in a similar context, suggesting PB-718 could offer a valuable treatment option for patients [7][8] Market Context - The MASH patient population is projected to reach 486 million by 2030, with a market potential of $100 billion, highlighting a significant unmet medical need [6] - The competitive landscape for GLP-1 drugs is intensifying, with Eli Lilly's tirzepatide showing strong growth and capturing a larger market share compared to Novo Nordisk's offerings, indicating a shift in market dynamics [10][11] - Pague Biopharma's innovative products, including PB-718 and the GLP-1 receptor agonist PB-119, are expected to enhance the company's market position and valuation, with the potential to become a leading player in the GLP-1 space [9][14] Investment Outlook - The ongoing innovation in the pharmaceutical sector, particularly in the GLP-1 market, is expected to drive significant valuation increases for companies like Pague Biopharma, which is well-positioned to capitalize on the growing demand for effective treatments [14] - The recent trends in the Hong Kong stock market, coupled with favorable macroeconomic conditions, suggest a strong potential for continued investment in the biotech sector, particularly for companies with robust product pipelines [14]

公司名稱: 派格生物醫藥 ( 杭州 ) 股份有限公司 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 致：香港交易及結算所有限公司 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | | 於香港聯交所上市 (註1) | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 非上市股份 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 106,791,193 | RMB | | 1 RMB | | 106,791,193 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 106,791,193 | RMB | | 1 RMB | | 106,791,193 | 本月底法定 ...

Core Viewpoint - The Hong Kong IPO market is active, with 57 new listings and a total fundraising amount of 131.9 billion HKD as of August 25. However, many companies face challenges in meeting both domestic and Hong Kong regulatory requirements for listing [1]. Group 1: Hong Kong IPO Overview - As of August 25, 2023, there have been 57 new IPOs on the Hong Kong Stock Exchange, raising a total of 131.9 billion HKD [1]. - There are currently 211 companies that have submitted applications for listing in Hong Kong [1]. Group 2: Listing Challenges - Companies looking to list in Hong Kong must comply with both domestic laws and Hong Kong's regulatory framework, making the IPO preparation process complex and demanding [1]. Group 3: Resources for Companies - A compilation of Hong Kong listing rules and disclosure documents for domestic companies planning to list in Hong Kong has been organized to assist businesses in understanding the latest regulatory dynamics [1].

Core Viewpoint - The stock of Peijia Medical (02565) has risen over 7%, reaching a new high of HKD 38.66, following the release of its interim results and the acceptance of its NDA for PB-119 by the National Medical Products Administration of China [1] Financial Performance - The company reported other net income of RMB 178,000 and R&D expenses of RMB 26.294 million, with a loss per share of RMB 0.25 [1] - The trading volume reached HKD 18.8928 million at the time of reporting [1] Product Development and Strategy - Peijia Medical anticipates commercializing PB-119 in China soon, following the acceptance of its NDA [1] - The company has successfully established a pipeline of six investigational drugs targeting chronic diseases [1] - The core strategy focuses on treating metabolic diseases and their complications, with multiple candidate drugs showing dual value potential as "first-in-class" (FIC) and "best-in-class" (BIC) [1]

Core Viewpoint - The stock of Peijia Medical (02565) has risen over 7%, reaching a new high of HKD 38.66, following the release of its interim performance report, indicating positive market sentiment towards the company's future prospects [1] Financial Performance - The company reported other net income of RMB 178,000 and research and development expenses of RMB 26.294 million, with a loss per share of RMB 0.25 [1] Product Development and Commercialization - Peijia Medical's NDA for PB-119 has been accepted by the National Medical Products Administration, with expectations for commercialization in China soon [1] - The company anticipates that post-listing, it will incur costs related to its operations as a public company, with financial performance expected to fluctuate based on the development status of candidate drugs, potential collaboration timelines, and regulatory approval schedules [1] Strategic Focus - The company has successfully established a pipeline matrix covering six investigational drugs targeting chronic diseases [1] - Peijia Medical's core strategy focuses on the treatment of metabolic diseases and their complications, with multiple candidate drugs showing dual value potential as "first-in-class" (FIC) and "best-in-class" (BIC), laying a solid foundation for future market competitiveness [1]

Group 1 - The company announced the resignation of Ms. Chan Wan Mei as the co-company secretary, authorized representative, and legal process agent effective from August 26, 2025 [1] - Mr. Zou Xinglong has been appointed as the new co-company secretary, authorized representative, and legal process agent, effective from August 26, 2025 [1] - Mr. Huang Yifeng will continue to serve as another co-company secretary [1]

Group 1 - The company announced the resignation of Ms. Chan Wan Mei as the co-secretary, authorized representative, and legal process agent effective from August 26, 2025 [1] - Mr. Zou Xinglong has been appointed as the co-secretary, authorized representative, and legal process agent effective from August 26, 2025, following Ms. Chan's resignation [1] - Mr. Huang Yifeng will continue to serve as another co-secretary [1]

Group 1 - The company announced the resignation of Chan Wan Mei as the co-secretary and authorized representative [1] - Zou Xinglong has been appointed as the new co-secretary, authorized representative, and legal process agent, effective from August 26, 2025 [1] - Huang Yifeng will continue to serve as another co-secretary [1]

Core Insights - The company reported a net income of RMB 178,000 for the six months ending June 30, 2025, with R&D expenses amounting to RMB 26.294 million and a loss per share of RMB 0.25 [1] - Significant progress has been made in technological innovation, product pipeline, and business operations in both the US and China [1] - The company has established a pipeline of six investigational drugs targeting chronic diseases, focusing on the treatment of metabolic diseases and their complications [1] Financial Performance - The company recorded a net income of RMB 178,000 for the reporting period [1] - R&D expenditures totaled RMB 26.294 million [1] - The loss per share was reported at RMB 0.25 [1] Product Development - The company’s core strategy emphasizes continuous innovation in the treatment of metabolic diseases [1] - Multiple candidate drugs are assessed to have dual value potential as "first-in-class" (FIC) and "best-in-class" (BIC) [1] - The NDA for PB-119 has been accepted by the National Medical Products Administration, with expectations for commercialization in China soon [1] Future Outlook - The company anticipates that financial performance will fluctuate due to the development status of candidate drugs, potential collaboration timelines, regulatory approval schedules, and commercialization efforts [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 鄒先生以優異成績取得英國曼徹斯特都會大學(Manchester Metropolitan University)英國及香港法律學士程度文憑（專業共同試），並於香港理工大學取得 企業管治碩士學位。 1 PegBio Co., Ltd. 派格生物醫藥（杭州）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2565） 變更聯席公司秘書、授權代表及法律程序代理人；及 豁免嚴格遵守上市規則第3.28及8.17條 派格生物醫藥（杭州）股份有限公司（「本公司」，連同其附屬公司統稱「本集團」） 董事（「董事」）會（「董事會」）謹此宣佈，陳婉梅女士（「陳女士」）已提呈辭任本公 司聯席公司秘書（「聯席公司秘書」）、香港聯合交易所有限公司（「聯交所」）證券上 市規則（「上市規則」）第3.05條項下之授權代表（「授權代表」）及根據上市規則第 19A.13(2)條及香港法例第622章公司條例第16部所規定代表 ...